884654-19-7

Basic information

• Product Name: 6-(2,2-diphenyl-ethylamino)-9-((1R,4S)-4-hydroxy-cyclopent-2-enyl)-9H-purine-2-carboxylic acid methyl ester
• Synonyms: 6-(2,2-diphenyl-ethylamino)-9-((1R,4S)-4-hydroxy-cyclopent-2-enyl)-9H-purine-2-carboxylic acid methyl ester
• CAS NO: 884654-19-7
• Molecular Weight: 455.516
• Mol File: 884654-19-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6-(2,2-diphenyl-ethylamino)-9-((1R,4S)-4-hydroxy-cyclopent-2-enyl)-9H-purine-2-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2,2-diphenyl-ethylamino)-9-((1R,4S)-4-hydroxy-cyclopent-2-enyl)-9H-purine-2-carboxylic acid methyl ester(884654-19-7)
• EPA Substance Registry System: 6-(2,2-diphenyl-ethylamino)-9-((1R,4S)-4-hydroxy-cyclopent-2-enyl)-9H-purine-2-carboxylic acid methyl ester(884654-19-7)

Safety Data

• Hazardous Substances Data: 884654-19-7(Hazardous Substances Data)

Upstream product

• 313345-04-9 6-(2,2-diphenyl-ethylamino)-9H-purine-2-carboxylic acid methyl ester 
• 60410-16-4 (1R,4S)-4-hydroxy-2-cyclopentene-1-yl acetate 
• 955136-01-3 6-(2,2-diphenyl-ethylamino)-9H-purine-2-carboxylic acid methyl ester hydrochloride 
• 60176-77-4 (1S,4R)-4-hydroxy-2-cyclopentenyl acetate 

Downstream Products

• 884654-21-1 9-((1R,4S)-4-di-tert-butoxycarbonylamino-cyclopent-2-enyl)-6-(2,2-diphenyl-ethylamino)-9H-purine-2-carboxylic acid methyl ester 
• 884654-20-0 6-(2,2-diphenyl-ethylamino)-9-((1R,4S)-4-ethoxycarbonyloxy-cyclopent-2-enyl)-9H-purine-2-carboxylic acid methyl ester 

Relevant articles and documents

Organic Compounds

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R1, R2 and R3 are as defined herein.

ORGANIC COMPOUNDS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein Rl, R2 and R3 are as defined herein.

PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS

Compounds of formula (I) in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.